- Best Trades Now: Energy, Defense, Food & More
- Why Markets Want Fannie, Freddie to Be Resolved
- Prescriptions for Fannie and Freddie
- Two Economic Indicators Show Continued Weakness
- Bonds Traders Prefer Fannie and Freddie Over Treasurys
- Jobless Claims Dip, But Overall Level Remains High
- Burger King Profit Up, Shares Fall on Margins
- Heinz Profit Rises, Beats Expectations
- UK Retail Sales Post Surprise Rise in July
- CSX 'Welcoming' Work With Activist Hedge Funds: CEO
- Heinz CEO: Ketchup 'Better Than Vodka' in Russia
- Video: Morningstar Anti-Recession Funds
- Segway Polo Nerds; Also: Your Mortgage Hardball E-Mails
- Hot Sauce, Tepid Stock?
- Cramer: Lehman's a 'Lurking Black Hole'
- Fast Money Now – Bove Upgrades Lehman, Other Mid-Day Trades for Thursday
- Warren Buffett's Canadian Oil Sands Tour Has Omaha Connection
- Vista & Seinfeld: Not That There's Anything Wrong with That
An experimental osteoporosis drug that is considered to be crucial to the future of biotechnology giant Amgen strengthened bones more than today's most widely-used treatment, research showed.
Researchers report at a scientific conference in Spain today that the twice-a-year injectable drug known as D-mab increased bone mineral density - a key measure of its effectiveness - 40 percent more than Fosamax.
Doctors say the 1100 women on Amgen's [AMGN
Loading...
()
] D-mab or on Fosamax experienced similar side effects including joint and back pain, indigestion and constipation.
In a press release, the company did not mention any infections, which some analysts have recently expressed concern over.
Results of a much bigger, 8,000-patient D-mab study that will likely determine the drug's fate are expected later this year.
Fosamax is made by Merck [MRK
Loading...
()
], but went generic a few months ago.
The detailed data out today confirm headline results that Amgen released back in January.
Print
Email
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes